News | Prostate Cancer | December 22, 2016

Phase II for Development of PSMA-targeted Radionuclide Therapy for Prostate Cancer

Cancer Targeted Technology Commences Second Phase of a $2.3M Contract to Develop an Innovative PSMA-targeted Radionuclide Therapy for Prostate Cancer

 

prostate, CT scan, Dave Fornell medical

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics and therapeutics, announced that the National Cancer Institute exercised the $2M Phase II option of a Small Business Innovation Research (SBIR) Phase I/II fast-track $2.3M contract to develop a new agent to treat metastatic prostate cancer. The contract develops a promising unique radiotherapeutic drug, CTT1403, that targets Prostate-Specific Membrane Antigen (PSMA). PSMA is over-expressed on prostate cancer and expression increases as the cancer metastasizes and becomes castrate-resistant. CTT’s unique phosphoramidate-based agents, bind irreversibly to PSMA and unlike other agents targeting PSMA, this distinctive mode of binding enhances uptake and internalization by tumor cells leading to increased accumulation of the therapeutic payload and improved efficacy.

In the Phase I $300K portion of the contract, conducted earlier in 2016, CTT successfully synthesized, tested and identified its lead drug, CTT1403. In addition to the PSMA targeting core, CTT1403 incorporates a chemical motif to increase circulation time, increase tumor uptake and decrease any binding to normal tissues. CTT1403, labeled with lutetium-177, demonstrated excellent circulation times in animal studies and cured 75% of mice implanted with human prostate tumors. CTT is working with Carolyn Anderson, M.D., professor of medicine, at University of Pittsburgh, to evaluate CTT1403 in mouse models of prostate cancer.

Anderson commented: "We are excited to continue our collaboration with CTT. The data from the first phase of the contract are promising, and we look forward to furthering this investigation to translate CTT1403 into human studies.”

The Phase II $2M portion advances CTT1403 into Investigational New Drug (IND) enabling studies, including manufacturing, additional pharmacology and safety assessments. These IND studies will support the initial clinical trial in metastatic prostate cancer. CTT’s strategic plan to identify, target, treat and monitor metastatic prostate cancer, employs CTT1403 as a companion therapeutic agent to CTT’s diagnostic Positron Emission Tomography (PET) agent, CTT1057, that commenced clinical trials in November 2016 to image metastatic sites in patients with prostate cancer.

“We have rationally designed CTT1403 to maximize tumor uptake, while minimizing side effects, and the drug is demonstrating exceptional targeting to prostate tumors in animal models,” stated Beatrice Langton-Webster, Ph.D., CEO of CTT and Principal Investigator on the contract. “We were very excited to see substantial increases in survival times in mice implanted with human prostate tumors. CTT1403 holds great promise as a treatment that will result in meaningful increases in life expectancy for men suffering from prostate cancer.”

For more information: www.cancertargetedtechnology.com/

Related Content

Recommendations address when and how radiation therapy should be used and outline best practices for patient-centered care

Figure 1. The guideline also includes treatment algorithms for initial local management (Figure 1) and local management following an unplanned excision (Figure 2).

News | Radiation Therapy | July 27, 2021
July 27, 2021 — A ...
The 15-ton compact accelerator is lifted into the David C. Pratt Cancer Center at Mercy St. Louis. (Photo: Business Wire)

The 15-ton compact accelerator is lifted into the David C. Pratt Cancer Center at Mercy St. Louis. (Photo: Business Wire)

News | Radiation Oncology | July 21, 2021
July 23, 2021 — Mevion Medical Systems announced that it has delivered the 15-ton compact accelerator to...
ASTRO just issued the following statement in response to the Radiation Oncology Model update in yesterday's HOPPS proposed rule, which compounds significant and detrimental cuts to the cancer care specialty in the proposed 2022 MPFS

Getty Images

News | Radiation Therapy | July 20, 2021
July 20, 2021 — In response to consecutive weeks of proposed...
Artificial intelligence-powered diagnostic tool spots asymptomatic prostate cancer in seconds

(L-R) Associate Professor Peter Brotchie (St Vincent's), Dr Ruwan Tennakoon (RMIT), Professor John Thangarajah (RMIT), Dr Mark Page (St Vincent's). Image courtesy of St Vincent's Hospital Melbourne

News | Prostate Cancer | July 19, 2021
July 19, 2021 — Prostate cancer is the most diagnosed
Ramon Alfredo Siochi, Ph.D. — the director of medical physics at WVU — led a task group to help ensure the accuracy of data that dictates a cancer patient's radiation therapy.

Ramon Alfredo Siochi, director of medical physics at West Virginia University. Image courtesy of WVU Photo/Aira Burkhart

News | Radiation Oncology | July 15, 2021
July 15, 2021 — Just as helicopter traffic reporters use their "bird's eye view" to route drivers around roadblocks s
Most countries have not introduced nationwide prostate cancer screening, as current methods result in overdiagnoses and excessive and unnecessary biopsies. A new study by researchers at Karolinska Institutet in Sweden, which is published in The New England Journal of Medicine, indicates that screening by magnetic resonance imaging (MRI) and targeted biopsies could potentially cut overdiagnoses by half.

Getty Images

News | Prostate Cancer | July 12, 2021
July 12, 2021 — Most countries have not introduced nationwide...
To help enhance the images and information provided to clinicians for radiation oncology treatment planning, GE Healthcare will integrate Spectronic Medical’s AI-based software with its industry leading AIR Recon DL technology
News | Artificial Intelligence | July 09, 2021
July 9, 2021 — GE Healthcare announced the integration of S...

Image courtesy of RaySearch

Feature | Treatment Planning | July 07, 2021 | Information provided by Grand View Research